After 18 years of living with multiple myeloma, Sally Kalksma has learned that getting through cancer treatment is about more ...
Researchers are studying whether combining CAR-T cell therapy with targeted drugs could help children with high-risk leukemia ...
In the latest installment of CURE's "Text a Survivor" series, Brad Moore answers some of the most common questions people have about living with and beyond a colorectal cancer diagnosis.
Researchers are studying whether combining CAR-T cell therapy with targeted drugs could help children with high-risk leukemia, including infants whose cancer may be more likely to return after ...
A partially randomized patient-preference design showed intervention receipt, not preference congruence, drove improvements in fatigue, sleep, and pain interference among distressed post-treatment ...
The omnipresence of pink during awareness campaigns can function as an involuntary cue for trauma recall, reactivating ...
Paxalisib blocks the PI3K/mTOR pathway, which plays a role in cancer cell growth and survival, but researchers have also ...
In the latest installment of CURE's "Text a Survivor" series, Brad Moore answers some of the most common questions people have about living with and beyond a colorectal cancer diagnosis.
After facing multiple cancers and hospice care, April Floyd credits her service dog Onyx with helping her find comfort, ...
FDA approves Inluriyo plus Verzenio for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast ...
FDA cleared BRAVNETSA for adult SSTR+ GEP-NETs spanning foregut, midgut, and hindgut sites, adding a second approved lutetium Lu 177 dotatate radiopharmaceutical option. ANDA-based approval ...
Paxalisib, first studied in brain cancer, may help HR+ breast tumors respond to CDK4/6 inhibitors again, based on early lab data.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results